Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 100

1.

Cutaneous toxicities of RAF inhibitors.

Anforth R, Fernandez-Peñas P, Long GV.

Lancet Oncol. 2013 Jan;14(1):e11-8. doi: 10.1016/S1470-2045(12)70413-8. Review.

PMID:
23276366
[PubMed - indexed for MEDLINE]
2.

[Adverse skin reactions induced by BRAF inhibitors: a systematic review].

Sibaud V, Lamant L, Maisongrosse V, Delord JP.

Ann Dermatol Venereol. 2013 Aug-Sep;140(8-9):510-20. doi: 10.1016/j.annder.2013.02.031. Epub 2013 Jun 19. Review. French.

PMID:
24034635
[PubMed - indexed for MEDLINE]
3.

Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.

Falchook GS, Long GV, Kurzrock R, Kim KB, Arkenau TH, Brown MP, Hamid O, Infante JR, Millward M, Pavlick AC, O'Day SJ, Blackman SC, Curtis CM, Lebowitz P, Ma B, Ouellet D, Kefford RF.

Lancet. 2012 May 19;379(9829):1893-901. doi: 10.1016/S0140-6736(12)60398-5.

PMID:
22608338
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma.

Anforth RM, Blumetti TC, Kefford RF, Sharma R, Scolyer RA, Kossard S, Long GV, Fernandez-Peñas P.

Br J Dermatol. 2012 Nov;167(5):1153-60. doi: 10.1111/j.1365-2133.2012.11155.x. Epub 2012 Oct 5.

PMID:
22804352
[PubMed - indexed for MEDLINE]
5.

Cutaneous effects of BRAF inhibitor therapy: a case series.

Mattei PL, Alora-Palli MB, Kraft S, Lawrence DP, Flaherty KT, Kimball AB.

Ann Oncol. 2013 Feb;24(2):530-7. doi: 10.1093/annonc/mds292. Epub 2012 Oct 3.

PMID:
23035153
[PubMed - indexed for MEDLINE]
Free Article
6.

Dabrafenib and its potential for the treatment of metastatic melanoma.

Menzies AM, Long GV, Murali R.

Drug Des Devel Ther. 2012;6:391-405. doi: 10.2147/DDDT.S38998. Epub 2012 Dec 11. Review.

PMID:
23251089
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study.

Larkin J, Del Vecchio M, Ascierto PA, Krajsova I, Schachter J, Neyns B, Espinosa E, Garbe C, Sileni VC, Gogas H, Miller WH Jr, Mandalà M, Hospers GA, Arance A, Queirolo P, Hauschild A, Brown MP, Mitchell L, Veronese L, Blank CU.

Lancet Oncol. 2014 Apr;15(4):436-44. doi: 10.1016/S1470-2045(14)70051-8. Epub 2014 Feb 27.

PMID:
24582505
[PubMed - indexed for MEDLINE]
8.

Clinical development of dabrafenib in BRAF mutant melanoma and other malignancies.

Gibney GT, Zager JS.

Expert Opin Drug Metab Toxicol. 2013 Jul;9(7):893-9. doi: 10.1517/17425255.2013.794220. Epub 2013 Apr 29. Review.

PMID:
23621583
[PubMed - indexed for MEDLINE]
9.

Ipilimumab, vemurafenib, dabrafenib, and trametinib: synergistic competitors in the clinical management of BRAF mutant malignant melanoma.

Luke JJ, Hodi FS.

Oncologist. 2013 Jun;18(6):717-25. doi: 10.1634/theoncologist.2012-0391. Epub 2013 May 24. Review.

PMID:
23709751
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Which drug, and when, for patients with BRAF-mutant melanoma?

Jang S, Atkins MB.

Lancet Oncol. 2013 Feb;14(2):e60-9. doi: 10.1016/S1470-2045(12)70539-9. Review.

PMID:
23369684
[PubMed - indexed for MEDLINE]
11.

[Melanoma: from molecular studies to the treatment breakthrough].

Imianitov EN.

Arkh Patol. 2013 Sep-Oct;75(5):63-72. Review. Russian.

PMID:
24341237
[PubMed - indexed for MEDLINE]
12.

Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial.

Long GV, Trefzer U, Davies MA, Kefford RF, Ascierto PA, Chapman PB, Puzanov I, Hauschild A, Robert C, Algazi A, Mortier L, Tawbi H, Wilhelm T, Zimmer L, Switzky J, Swann S, Martin AM, Guckert M, Goodman V, Streit M, Kirkwood JM, Schadendorf D.

Lancet Oncol. 2012 Nov;13(11):1087-95. doi: 10.1016/S1470-2045(12)70431-X. Epub 2012 Oct 8.

PMID:
23051966
[PubMed - indexed for MEDLINE]
13.

Improved survival with vemurafenib in melanoma with BRAF V600E mutation.

Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, Hogg D, Lorigan P, Lebbe C, Jouary T, Schadendorf D, Ribas A, O'Day SJ, Sosman JA, Kirkwood JM, Eggermont AM, Dreno B, Nolop K, Li J, Nelson B, Hou J, Lee RJ, Flaherty KT, McArthur GA; BRIM-3 Study Group.

N Engl J Med. 2011 Jun 30;364(26):2507-16. doi: 10.1056/NEJMoa1103782. Epub 2011 Jun 5.

PMID:
21639808
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Vemurafenib for the treatment of melanoma.

Jordan EJ, Kelly CM.

Expert Opin Pharmacother. 2012 Dec;13(17):2533-43. doi: 10.1517/14656566.2012.737780. Epub 2012 Oct 24. Review.

PMID:
23094782
[PubMed - indexed for MEDLINE]
15.

Major clinical response to a BRAF inhibitor in a patient with a BRAF L597R-mutated melanoma.

Bahadoran P, Allegra M, Le Duff F, Long-Mira E, Hofman P, Giacchero D, Passeron T, Lacour JP, Ballotti R.

J Clin Oncol. 2013 Jul 1;31(19):e324-6. doi: 10.1200/JCO.2012.46.1061. Epub 2013 May 28. No abstract available.

PMID:
23715574
[PubMed - indexed for MEDLINE]
16.

Targeting brain metastases in patients with melanoma.

Papadatos-Pastos D, Soultati A, Harries M.

Biomed Res Int. 2013;2013:186563. doi: 10.1155/2013/186563. Epub 2013 Dec 23. Review.

PMID:
24455677
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Cutaneous adverse events associated with vemurafenib in patients with metastatic melanoma: practical advice on diagnosis, prevention and management of the main treatment-related skin toxicities.

Sinha R, Edmonds K, Newton-Bishop JA, Gore ME, Larkin J, Fearfield L.

Br J Dermatol. 2012 Nov;167(5):987-94. doi: 10.1111/bjd.12010. Review.

PMID:
22913467
[PubMed - indexed for MEDLINE]
18.

Paradoxical oncogenesis: are all BRAF inhibitors equal?

Menzies AM, Kefford RF, Long GV.

Pigment Cell Melanoma Res. 2013 Sep;26(5):611-5. doi: 10.1111/pcmr.12132. Epub 2013 Jul 19.

PMID:
23795808
[PubMed - indexed for MEDLINE]
19.

Panniculitis with arthralgia in patients with melanoma treated with selective BRAF inhibitors and its management.

Zimmer L, Livingstone E, Hillen U, Dömkes S, Becker A, Schadendorf D.

Arch Dermatol. 2012 Mar;148(3):357-61. doi: 10.1001/archdermatol.2011.2842. Epub 2012 Jan 16.

PMID:
22250191
[PubMed - indexed for MEDLINE]
20.

Vemurafenib in melanoma.

Shaw HM, Nathan PD.

Expert Rev Anticancer Ther. 2013 May;13(5):513-22. doi: 10.1586/era.13.24. Review.

PMID:
23617343
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk